Development of new methods to accurately measure heart disease outcomes
- Years funded:
- 2018 - 2020
Australian government spends $7.7 billion annually to treat cardiovascular disease (CVD).
To identify the most cost-effective strategies from a myriad of interventions and to allocate resources efficiently, precise effectiveness measurement is of utmost importance.
Quality Adjusted Life Years (QALYs) is commonly used as a measure of health outcome in economic evaluation and health utility is the component of QALY that accounts for quality of life (QoL) associated with given health states.
Typically, health utility is measured using a generic (across all disease states) multi-attribute utility instrument (MAUI). However, there is compelling evidence to suggest that the outcome of economic evaluations may vary due to the constructs of generic MAUIs.
Just as clinical researchers have developed disease specific QoL instruments, researchers have been developing disease-specific MAUIs in response to this problem. Hence, in the absence of CVD-specific MAUIs, decision makers involved in clinical and cost-effectiveness evaluation currently have no option but to use generic MAUIs. This has profound implications on economic evaluation of CVD strategies.
A MAUI consist of a classification system and a utility algorithm. A CVD specific classification system has been built by this investigator. This study will validate and develop the utility algorithm for the new classification system.
Dr Sanjeewa Kularatna
|Institute:||Queensland University of Technology|